<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604004</url>
  </required_header>
  <id_info>
    <org_study_id>NUD_04_12</org_study_id>
    <nct_id>NCT02604004</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet 150 mg (Test) and EPIVIR of Glaxosmithkline in Healthy Volunteers of Both Genders in Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to check whether the test drug (lamivudine in the form of
      coated tablet 150 mg) achieves plasma levels equivalent to those obtained from the EPIVIR in
      the form of coated tablet 150 mg GlaxoSmithKline administered to 28 volunteers of both genres
      under fasting condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open, randomized, crossover 2x2, single dose, with the administration of medicine
      with 28 healthy volunteers, adults aged 18-50 years, of both genders (14 males and 14
      females). Of the 28 volunteers planned in the study protocol to start, gave up one (woman)
      before the start of Phase I. So the study was initiated and completed with the participation
      of 27 volunteers. The volunteers were in hospital for a period of approximately 36 hours in
      each stage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Up to 36 hours</time_frame>
    <description>Area under the Plasma concentration-time curve from time Zero to last time (AUCinf) of lamivudine in plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 36 hours</time_frame>
    <description>Maximum concentration (Cmax) of lamivudine in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 36 hours</time_frame>
    <description>Time for Maximum concentration (Tmax) of lamivudine in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Terminal half-time of lamivudine in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Up to 36 hours</time_frame>
    <description>Area under the Plasma concentration-time curve from time Zero to infinity (AUCinf) of lamivudine in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV INFECTIONS</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epivir ® tablet 150-mg single dose (drug reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamivudine 150-mg tablet single dose (drug test)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epivir ® tablet 150-mg single dose (drug reference)</intervention_name>
    <description>Bioequivalence lamivudine 150 mg tablets fasting condition</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <other_name>lamivudine</other_name>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine 150-mg tablet single dose (drug test)</intervention_name>
    <description>Bioequivalence lamivudine 150 mg tablets fasting condition</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Considered healthy after undergoing a clinical evaluation;

          -  Agree freely and sign the Recruitment and Informed Consent Term, after all the content
             of the protocol was clear before any procedure;

          -  Present the body mass index greater than 19 and less than 30.

        Exclusion Criteria:

          -  Results of laboratory tests outside the range considered normal, unless they were
             considered clinically irrelevant;

          -  Allergic to lamivudine or any other drug;

          -  Positive outcome of the pre-admission pregnancy test;

          -  Regular medication within four (4) weeks prior to the start of the study or use of any
             medication to present interaction with lamivudine one week before the start of the
             study;

          -  Use abusive alcoholic beverage;

          -  Use of illicit drugs and tobacco;

          -  History of liver disease, renal, pulmonary, gastrointestinal, epileptic, hematologic
             or psychiatric; hypo- or hypertension of any cause that required pharmacological
             treatment; myocardial infarction, angina and / or heart failure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Goodman &amp; Gilman's The Pharmacologic Basis of Therapeutics - 11th Ed. (2006)</citation>
  </results_reference>
  <results_reference>
    <citation>Martindale The Complete Drug Reference - Thirty-sixth edition (2009).</citation>
  </results_reference>
  <results_reference>
    <citation>http://www4.anvisa.gov.br/base/visadoc/BM/BM[25676-1-0].PDF acessado em 13/10/2011.</citation>
  </results_reference>
  <results_reference>
    <citation>ANVISA. Manual de Boas Práticas em Biodisponibilidade/ Bioequivalência. Volume I. Agência Nacional de Vigilância Sanitária. Brasília: ANVISA, 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>ANVISA. Resolução RE nº 899, de 29 de maio de 2003. &quot;Guia para validação de métodos analíticos e bioanalíticos&quot;. ANVISA-MS, Brasília.</citation>
  </results_reference>
  <results_reference>
    <citation>ANVISA. Resolução RE nº 1170, de 19 de abril de 2006. &quot;Guia para provas de biodisponibilidade relativa/ bioequivalência de medicamentos&quot;. ANVISA-MS, Brasília.</citation>
  </results_reference>
  <results_reference>
    <citation>ANVISA. &quot;Guia para planejamento e realização da etapa estatística de estudos de Biodisponibilidade relativa / Bioequivalência&quot;. RE Nº. 898, de 29 de maio de 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Kano EK, dos Reis Serra CH, Koono EE, Andrade SS, Porta V. Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies. Int J Pharm. 2005 Jun 13;297(1-2):73-9. Epub 2005 Apr 26.</citation>
    <PMID>15907596</PMID>
  </results_reference>
  <results_reference>
    <citation>Narang VS, Lulla A, Malhotra G, Purandare S. Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):566-9.</citation>
    <PMID>15793367</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107-21. Review. Erratum in: Clin Pharmacokinet. 2004;43(11):732.</citation>
    <PMID>12537512</PMID>
  </results_reference>
  <results_reference>
    <citation>Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, Scott L, Lester R. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology. 1981 Jun;80(6):1497-500.</citation>
    <PMID>7227774</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980 Oct;215(1):86-91.</citation>
    <PMID>7452494</PMID>
  </results_reference>
  <results_reference>
    <citation>FLOCKHART D. A. Drug interactions: Cytochrome P450 drug interaction table. Indiana School of Medicine. 2007. http://medicine.iupui.edu/clinpharm/ddis/ table.asp. Accessed December 1, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009 Dec;6(4):522-43. doi: 10.1016/j.genm.2009.12.004. Review.</citation>
    <PMID>20114004</PMID>
  </results_reference>
  <results_reference>
    <citation>Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007 Jun;4(2):106-19. Review.</citation>
    <PMID>17707845</PMID>
  </results_reference>
  <results_reference>
    <citation>Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB, et al. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995 Jun;171(6):1438-47.</citation>
    <PMID>7769277</PMID>
  </results_reference>
  <results_reference>
    <citation>van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995 May;171(5):1166-71.</citation>
    <PMID>7751691</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999 Jan;36(1):41-66. Review.</citation>
    <PMID>9989342</PMID>
  </results_reference>
  <results_reference>
    <citation>Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997 Apr;53(4):657-80. Review.</citation>
    <PMID>9098665</PMID>
  </results_reference>
  <results_reference>
    <citation>World Medical Association Declaration of Helsinki (WMA). Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 7, 2000 [WMA Web site]. http://www.wma.net/e/policy/b3.htm . Accessed December 20, 2009</citation>
  </results_reference>
  <results_reference>
    <citation>Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations [COER Web site). http://www.fda.gov/cder/guidance/5356ful.pdf. Accessed February 22, 2010.</citation>
  </results_reference>
  <results_reference>
    <citation>EMEA (European Agency for the Evaluation of Medicinal Products). CPMP (Committee for Propietary Medicinal Products). Note for guidance on the investigation of bioavailability and bioequivalence. London, July 2001.</citation>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Pernambuco</investigator_affiliation>
    <investigator_full_name>José Homero de Souza Filho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lamivudine</keyword>
  <keyword>bioequivalence test</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>high-performance liquid chromatography</keyword>
  <keyword>3TC</keyword>
  <keyword>LC-MS/MS</keyword>
  <keyword>mass spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

